Elanco Animal Health (ELAN) news

Biocon's Shaw: Biosimilars a very attractive segment

Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in…

Neurizon Therapeutics - Sergio Duchini transitions to non-executive chairman

Neurizon Therapeutics Limited (ASX: NUZ) has announced that Sergio Duchini has transitioned from the role of Chief Executive Officer to Non-Executive Chairman of the Board , effective September 7, 2026. This change follows the appointment of Dr. Michael Thurn as the company’s new Chief Executive…

Neurizon Therapeutics Ltd-Elanco representative appointed as Neurizon board observer

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) has announced appointment of Ms Justine Conway as a Board Observer, effective November 26, 2025. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN) and will represent Elanco in…

Elanco Animal Health Inc outlook Q3 adj EPS $0.19 - $0.22

Elanco Animal Health shares up 6.5% premarket after Q2 results beat

Elanco Animal Health (NYSE: ELAN) shares rose 6.5% in premarket trading following the release of its second-quarter financial results, which exceeded expectations. The company reported stronger-than-anticipated earnings, driven by solid performance across its product portfolio and operational…